Home » Topics » BioWorld Science

BioWorld Science
RSS

5-HT1 agonists described by Merck & Co.

Aug. 9, 1996

Actiq to undergo phase III clinical trials

Aug. 9, 1996

Menarini and Lilly sign comarketing agreement

Aug. 9, 1996

Raloxifene claimed as treatment for excess bradykinin-related conditions

July 26, 1996

Comparative study results of Systen and Menorest

July 26, 1996

Prostaglandin E1 regimen shows positive results for male erectile dysfunction

July 26, 1996

ALT-766: New AGE cross-link breaker from Alteon

July 26, 1996

Phase III results indicate Ergoset's effectiveness and safety

July 26, 1996

Selective beta3-adrenoceptor agonists in Dainippon's pipeline

July 26, 1996

CL-316243: Claimed as gastrointestinal disorders treatment by Glaxo Wellcome

July 26, 1996

Popular Stories

Today's news in brief
BioWorld
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
Japan endorses two iPSC drugs for approval under CEA pathway
BioWorld
Japan is backing conditional approvals of Amchepry (raguneprocel, Sumitomo Pharma Co. Ltd./Racthera Co. Ltd.) and Reheart (Cuorips Inc.), positioning them to...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 24, 2026
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...